Clinical Research, Pharma & Healthcare FinancingRemegen Announces Phase 3 Trial Results of Telitacicept for gMGPR NewswireApril 9, 2025August 1, 2025 by PR NewswireApril 9, 2025August 1, 20250203 On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in...
